|
Categories |
|
Cardiovascular |
|
|
Biotechnology
Cancer
Consumer
Customer
Relationship Management
Drug
Delivery
eHealthcare
Pharma
eHealthcare
Physician
Generics
Healthcare
Medical
Devices
OTC
Pharmaceuticals
Pharmaceuticals
Pharmacoeconomics
Therapeutic
Areas:
- Cardiovascular
- Central
Nervous System
- Immune
Disorders and Inflammation
- Infectious
Diseases
- Oncology
-
Women'sHealth
|
|
|
1- PROactive Results - The Diabetes Trial That Could Have Been
10-Nov-2005
A critical evaluation of the PROactive trial, delivered in a concise, accessible format. Discusses the rationale and study design of the trial, presents the results, and provides independent commentary.
------------------------------------------------------------------------------------------------------------------------- |
2- Hypertension and Diabetic Kidney Disease - Prevalence, current treatment and future options
25-Oct-2005
An evaluation of the current and future potential in the diabetic nephropathy market based on reviews of current treatment options, future treatment opportunities and epidemiological data on the progression of diabetic kidney disease in hypertensives.
------------------------------------------------------------------------------------------------------------------------- |
3- Stakeholder Insight: Dyslipidemia - Statins Dominate Treatment Pathway - For Now
05-Oct-2005
Analysis of current and future trends and opportunities in the management and treatment of dyslipidemia and its sub-populations, based on 180 physician interviews across the seven major markets and the views of key opinion leaders.
------------------------------------------------------------------------------------------------------------------------- |
4- Pipeline Insight: Antithrombotics - Anticoagulants and Antiplatelets Have Blockbuster Potential
04-Oct-2005
In-depth review of developmental antithrombotics in the anticoagulant, antiplatelet and thrombolytic classes. Assesses the commercial prospects of new agents against existing products and unmet market needs, and provides sales forecasts to 2015.
------------------------------------------------------------------------------------------------------------------------- |
5- Pipeline Insight: Antidyslipidemics - The Power of Two
09-Aug-2005
An in-depth, critical evaluation of compounds in development for dyslipidemia. It assesses the commercial prospects for the launch of innovative new products against the level of existing unmet needs, and provides event and sales forecasts to 2015.
------------------------------------------------------------------------------------------------------------------------- |
6- The Cardiovascular Market Outlook to 2010
01-Aug-2005
This report provides information on the prevalence and incidence of cardiovascular disease in the seven largest pharmaceutical markets in 2004, and provides forecast epidemiological data for major therapeutic indications over the period 2004 to 2010.
------------------------------------------------------------------------------------------------------------------------- |
7- Prevention of Coronary Heart Disease - Promoting Healthy Lifestyles
29-Jul-2005
Based on an analysis of the coronary heart disease market, this Market Brief assesses the size of the market, the consequences of suffering from coronary heart disease and what can be done to prevent atherosclerosis.
-------------------------------------------------------------------------------------------------------------------------
|
8- Commercial Insight: Antidiabetics - Billion Dollar Drugs, Pipeline Dreams?
27-Jul-2004
Analysis of the current status and future potential of the marketed antidiabetics drug classes across the seven major markets. Drug classes covered include sulfonylureas, biguanides, insulin, TZDs and prandial glucose regulators.
-------------------------------------------------------------------------------------------------------------------------
|
9- Commercial Insight: Antidyslipidemics - Cholesterol Absorption of Lipitor's Dominance
08-Jun-2005
An analysis of the current status and future potential of the marketed antidyslipidemic drug classes across the seven major markets. Drug classes covered include statins, fibrates, nicotinic acid and cholesterol uptake inhibitors.
-------------------------------------------------------------------------------------------------------------------------
|
10- Commercial Insight: Antithrombotics - Sanofi-Aventis
the Dominant Player
23-Dec-2004
An analysis of the current status and future
potential of the marketed antithrombotics drug classes across the
seven major markets. Drug classes covered include antiplatelets,
anticoagulants and
thrombolytics.------------------------------------------------------------------------------------------------------------------------- |
11- Trends in PCI - PCI vs. Thrombolysis: The
Debate
22-Dec-2004
Drug-eluting stents have become the gold
standard in percutaneous coronary intervention procedures;
biodegradable stents may become the future gold standard. The PCI
vs. thrombolysis debate seems to be falling firmly on the side of
PCI.------------------------------------------------------------------------------------------------------------------------- |
12- OTC Statins - The UK Experience
25-Nov-2004
A concise synopsis of the rationale for OTC
statin launch in the UK, with close analysis of launch and marketing
approach adopted by Johnson & Johnson. MSD in the UK and the
potential for OTC statins in other
markets.------------------------------------------------------------------------------------------------------------------------- |
13- Pipeline Insight: PAD - Gene Therapy Going Out on a
Limbl
23-Nov-2004
Current treatment options provide mainly
symptomatic relief. However, gene therapy has the potential to
provide a cure. The most promising appears to be Sanofi-Aventis's
NV1FGF, which is forecast to achieve sales of $687m in
2012.------------------------------------------------------------------------------------------------------------------------- |
14- Commercial Insight: Antihypertensives - Can
Manufacturers Maintain Value?
22-Oct-2004
An analysis of the current status and future
potential of the marketed antihypertensive drug classes across the
seven major markets. Drug classes covered include ARBs, ACE
inhibitors, Beta blockers CCBs and
diuretics.-------------------------------------------------------------------------------------------------------------------------
|
15- Pipeline Insight: Antihypertensives - Together
We Stand, Divided We Fail
6-Aug-2004
In-depth, critical evaluation of the compounds in
development for essential hypertension, including assessment of the
commercial prospects for the launch of innovative new products
against the level of existing unmet needs in this
market
------------------------------------------------------------------------------------------------------------------------- |
16- Diabetes and Pregnancy - Delivering Improved
Outcomes 29-June-2004
Review of treatment and
diagnosis of diabetes in pregnancy.
-------------------------------------------------------------------------------------------------------------------------
|
17- Landmark Anti-dyslipidemic Trials Update - How
Low Can You Go?
23-June-2004
Evaluation of data from recent clinical trials
supporting the use of intensive statin therapy and lower LDL
cholesterol target levels, and investigation of the current barriers
to the proposed therapeutic strategies.
-------------------------------------------------------------------------------------------------------------------------
|
18- Stakeholder Insight: Metabolic Syndrome - Ticking Time
Bomb 8-Jun-2004
Based on 388 physician interviews across seven major
markets, this report analyzes the current and future trends in
recognizing and treating metabolic syndrome and examines the
potential of existing and developmental therapies in this
population.
-------------------------------------------------------------------------------------------------------------------------
|
19- The Outlook for Cardiovascular Risk Factors:
Epidemiology, market and pipeline analysis Feb-2004
The Outlook for Cardiovascular
Risk Factors: Epidemiology, market and pipeline
analysis
-------------------------------------------------------------------------------------------------------------------------
|
20- Potential for Cross-Risk Factor
Combinations: Targeting Hypertension, Dyslipidemia and
Diabetes 1-Dec-2003
The epidemic
growth in the three main cardiovascular risk factors i.e.
dyslipidemia, hypertension and type 2 diabetes is resulting in a
heavy pill burden on multi-risk patients. One potential solution is
to combine therapies in a single pill.
-------------------------------------------------------------------------------------------------------------------------
|
21- Pipeline Insight: Antithrombotics - Entering the Era
of Exanta 14-Nov-2003
In-depth,
critical evaluation of the key anticoagulant and antiplatelet
R&D compounds, with an assessment of the commercial prospects of
innovative new products against the level of existing unmet needs in
this market
-------------------------------------------------------------------------------------------------------------------------
|
22- Anti-hypertensives: Landmark clinical trial update -
Commercial assessment of CHARM, COMET, EPHESUS and
EUROPA
4-Nov-2003
In depth
analysis of the market impact of the landmark trials that have been
announced since Market Dynamics: Anti-hypertensives was published.
These include CHARM, COMET, EPHESUS and
EUROPA.
-------------------------------------------------------------------------------------------------------------------------
|
23- Commercial Perspectives: Diabetes - Type 2 Epidemic
Driving Aggressive Therapy 4-Nov-2003
Detailed product profiles for the leading insulin and
oral antidiabetic brands and the impact of key events on current and
future market dynamics
-------------------------------------------------------------------------------------------------------------------------
|
24-
Diabetic Nephropathy: Prevalence, Progression,
Prevention and Potential
3-Oct-2003
An evaluation of
the current and future potential for the diabetic nephropathy market
based on epidemiology data of renal disease progression in type 2
diabetes, treatment guidelines and ongoing clinical
trials
-------------------------------------------------------------------------------------------------------------------------
|
25- The Cardiovascular Market Outlook to 2008
1-Oct-2003
The
Cardiovascular Market Outlook to 2008, is a comprehensive source of
market analysis of the most valuable therapy area within the global
pharmaceutical market; Valued at an estimated $73.7bn in 2002, the
global market for cardiovascular drugs grew by a moderate 2.5% over
2001 levels. But how much do you know about the fastest growing
cardiovascular (CV) segment? Who has the fastest growing CV
portfolio? And how will the market develop in the next five years?
All these questions and more are answered in this management
report.
-------------------------------------------------------------------------------------------------------------------------
|
26- Pipeline Insight: Anti-arrhythmics - Adjunctive Role
for Drugs in Hybrid Therapy 20-Aug-2003
In-depth
competitive analysis of the drugs and devices currently in
development for the treatment of arrhythmia and their likely impact
on currently marketed
products.
-------------------------------------------------------------------------------------------------------------------------
|
27- Pipeline Insight: Dyslipidemia - Shift from statins to
add-ons 11-Aug-2003
In-depth competitive analysis of the compounds
currently in development for the treatment of dyslipidemia and their
likely impact on currently marketed products
-------------------------------------------------------------------------------------------------------------------------
|
28- 2003 Cardiovascular Market Update: Part 2 -
Antithrombotics 8-Aug-2003
This brief provides a review of the cardiovascular
market in 2003, with a focus on antithrombotics. Use this report to
understand the key events impacting the future dynamics and the
leading brands within this market and to recognize the threats
facing the leading products and identify key opportunities for
R&D.
-------------------------------------------------------------------------------------------------------------------------
|
29- 2003 Cardiovascular Market Update: Part 1 -
Anti-hypertensives, Anti-dyslipidemics and Cardiac
Therapy 24-Jul- 2003
Review of the cardiovascular market in 2003,
with a focus on anti-hypertensives, anti-dyslipidemics and cardiac
therapies.
-------------------------------------------------------------------------------------------------------------------------
|
30- Treatment Algorithms: Secondary Prevention - Managing
Post-ACS Patients 25-Jun-2003
Analysis of current
and future trends in treatment for the prevention of recurrent
events following acute coronary
syndromes.
-------------------------------------------------------------------------------------------------------------------------
|
31- Statin Adjunct Therapy - Zetia, Revenue
Protection for Zocor? 26-May-2003
Analysis of the
role of adjunctive therapy in the treatment of dyslipidemia,
focusing on the factors driving versus limiting the future uptake of
Zetia
(ezetimibe).
-------------------------------------------------------------------------------------------------------------------------
|
32- Antithrombotics in Acute Ischemic Stroke - The Clot
Thickens 4-Apr-2003
Currently marketed antithrombotics for the treatment
of acute ischemic stroke.
-------------------------------------------------------------------------------------------------------------------------
|
33- Strategic Perspectives: Marketed Antithrombotics -
Plavix Adopts Lovenox's Developmental Defense Strategy
25-Mar-2003
In-depth analysis of the current antithrombotics
market and its future direction.
-------------------------------------------------------------------------------------------------------------------------
|
34- Commercial Perspectives: Drug-Eluting Stents Update -
Impact on the PCI Market 21-Mar-2003
Developments within the field of drug-eluting stents
over the past year, with a comprehensive review of clinical trial
data.
-------------------------------------------------------------------------------------------------------------------------
|
35- Market Dynamics: Anti-hypertensives - ALLHAT
'Landmark' Trial Old Hat? 18-Mar-2003
Dynamics and competitive positioning of leading
products in the anti-hypertensives
market.
-------------------------------------------------------------------------------------------------------------------------
|
36- Treatment Algorithms: Acute Coronary Syndromes -
Facilitating a Hybrid Approach to Therapy
17-Mar-2003
Analysis of
treatment patterns for acute coronary syndromes (ACS), including
unstable angina, non ST segment elevation myocardial infarction and
ST segment elevation myocardial
infarction.
-------------------------------------------------------------------------------------------------------------------------
|
37- Testing for C-reactive Protein - Impact of New AHA/CDC
Guidelines
3-Mar-2003
Commercial implications of the new AHA/CDC guidelines
on high-sensitivity C-reactive Protein
testing
--------------------------------------------------------------------------------------------------------------------------
|
38- Cardiovascular Epidemiology Estimates 2002 - >From
CV Risk Factors Through Chronic Disease to Acute Thrombotic Events
and Procedures
27-Jan-2003
Comprehensive
data and methodology for cardiovascular disease states in 7
countries.
-------------------------------------------------------------------------------------------------------------------------
|
| |
| |
| |
